Suppr超能文献

ARAF 蛋白激酶通过拮抗其与 RASGAP NF1 的结合来激活 RAS。

ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1.

机构信息

Molecular Pharmacology Program, Sloan Kettering Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Department of Medicine, Memorial Hospital, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

出版信息

Mol Cell. 2022 Jul 7;82(13):2443-2457.e7. doi: 10.1016/j.molcel.2022.04.034. Epub 2022 May 24.

Abstract

RAF protein kinases are effectors of the GTP-bound form of small guanosine triphosphatase RAS and function by phosphorylating MEK. We showed here that the expression of ARAF activated RAS in a kinase-independent manner. Binding of ARAF to RAS displaced the GTPase-activating protein NF1 and antagonized NF1-mediated inhibition of RAS. This reduced ERK-dependent inhibition of RAS and increased RAS-GTP. By this mechanism, ARAF regulated the duration and consequences of RTK-induced RAS activation and supported the RAS output of RTK-dependent tumor cells. In human lung cancers with EGFR mutation, amplification of ARAF was associated with acquired resistance to EGFR inhibitors, which was overcome by combining EGFR inhibitors with an inhibitor of the protein tyrosine phosphatase SHP2 to enhance inhibition of nucleotide exchange and RAS activation.

摘要

RAF 蛋白激酶是小 GTP 酶 RAS 结合态 GTP 的效应物,通过磷酸化 MEK 发挥作用。我们在这里表明,ARAF 的表达以激酶非依赖性的方式激活 RAS。ARAF 与 RAS 的结合将 GTP 酶激活蛋白 NF1 置换,并拮抗 NF1 介导的 RAS 抑制。这降低了 ERK 依赖性的 RAS 抑制作用,增加了 RAS-GTP。通过这种机制,ARAF 调节了 RTK 诱导的 RAS 激活的持续时间和后果,并支持 RTK 依赖性肿瘤细胞的 RAS 输出。在具有 EGFR 突变的人类肺癌中,ARAF 的扩增与对 EGFR 抑制剂的获得性耐药有关,通过将 EGFR 抑制剂与蛋白酪氨酸磷酸酶 SHP2 的抑制剂联合使用,可以克服这种耐药性,从而增强核苷酸交换和 RAS 激活的抑制作用。

相似文献

6
KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis.KRAS G13D 对神经纤维瘤介导的 GTP 水解的敏感性。
Proc Natl Acad Sci U S A. 2019 Oct 29;116(44):22122-22131. doi: 10.1073/pnas.1908353116. Epub 2019 Oct 14.

引用本文的文献

1
RAS signaling gets granular.RAS信号传导变得细化。
Nat Chem Biol. 2025 Mar 4. doi: 10.1038/s41589-025-01851-1.
4
Targeting RAF dimers in RAS mutant tumors: From biology to clinic.靶向RAS突变肿瘤中的RAF二聚体:从生物学走向临床。
Acta Pharm Sin B. 2024 May;14(5):1895-1923. doi: 10.1016/j.apsb.2024.02.018. Epub 2024 Feb 28.
5
Tumor biomarkers for diagnosis, prognosis and targeted therapy.肿瘤标志物用于诊断、预后和靶向治疗。
Signal Transduct Target Ther. 2024 May 20;9(1):132. doi: 10.1038/s41392-024-01823-2.
10
Rare molecular subtypes of lung cancer.肺癌的罕见分子亚型。
Nat Rev Clin Oncol. 2023 Apr;20(4):229-249. doi: 10.1038/s41571-023-00733-6. Epub 2023 Feb 20.

本文引用的文献

7
Accelerating Discovery of Functional Mutant Alleles in Cancer.加速癌症功能突变等位基因的发现。
Cancer Discov. 2018 Feb;8(2):174-183. doi: 10.1158/2159-8290.CD-17-0321. Epub 2017 Dec 15.
9
RAS Proteins and Their Regulators in Human Disease.人类疾病中的RAS蛋白及其调节因子
Cell. 2017 Jun 29;170(1):17-33. doi: 10.1016/j.cell.2017.06.009.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验